Therapeutic potency of mTOR signaling pharmacological inhibitors in the treatment of proinflammatory diseases, current status, and perspectives
Mammalian target of rapamycin (mTOR) signaling pathway controls cell energy metabolism. There is an interplay between mTOR and proinflammatory signaling pathways, supporting the role of the pathway in the pathogenesis of inflammatory diseases. Inhibition of mTOR signaling using specific pharmacologi...
Uloženo v:
| Vydáno v: | Journal of cellular physiology Ročník 233; číslo 6; s. 4783 - 4790 |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
Wiley Subscription Services, Inc
01.06.2018
|
| Témata: | |
| ISSN: | 0021-9541, 1097-4652, 1097-4652 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Mammalian target of rapamycin (mTOR) signaling pathway controls cell energy metabolism. There is an interplay between mTOR and proinflammatory signaling pathways, supporting the role of the pathway in the pathogenesis of inflammatory diseases. Inhibition of mTOR signaling using specific pharmacological inhibitors could offer therapeutic promise in several inflammatory‐associated diseases. In this review, we summarize recent findings on the regulatory effects of mTOR signaling on inflammation and the therapeutic potency of mTOR pharmacological inhibitors in the treatment of inflammatory diseases including cancer, neurodegenerative diseases, atherosclerosis, sepsis, and rheumatoid arthritis for a better understanding and hence a better management of these diseases.
In this review, we summarize recent findings on the regulatory effects of mTOR signaling on inflammation and the therapeutic potency of mTOR pharmacological inhibitors in the treatment of inflammatory diseases including cancer, neurodegenerative diseases, atherosclerosis, sepsis, and rheumatoid arthritis for a better understanding and hence a better management of these diseases. |
|---|---|
| AbstractList | Mammalian target of rapamycin (mTOR) signaling pathway controls cell energy metabolism. There is an interplay between mTOR and proinflammatory signaling pathways, supporting the role of the pathway in the pathogenesis of inflammatory diseases. Inhibition of mTOR signaling using specific pharmacological inhibitors could offer therapeutic promise in several inflammatory-associated diseases. In this review, we summarize recent findings on the regulatory effects of mTOR signaling on inflammation and the therapeutic potency of mTOR pharmacological inhibitors in the treatment of inflammatory diseases including cancer, neurodegenerative diseases, atherosclerosis, sepsis, and rheumatoid arthritis for a better understanding and hence a better management of these diseases. Mammalian target of rapamycin (mTOR) signaling pathway controls cell energy metabolism. There is an interplay between mTOR and proinflammatory signaling pathways, supporting the role of the pathway in the pathogenesis of inflammatory diseases. Inhibition of mTOR signaling using specific pharmacological inhibitors could offer therapeutic promise in several inflammatory-associated diseases. In this review, we summarize recent findings on the regulatory effects of mTOR signaling on inflammation and the therapeutic potency of mTOR pharmacological inhibitors in the treatment of inflammatory diseases including cancer, neurodegenerative diseases, atherosclerosis, sepsis, and rheumatoid arthritis for a better understanding and hence a better management of these diseases.Mammalian target of rapamycin (mTOR) signaling pathway controls cell energy metabolism. There is an interplay between mTOR and proinflammatory signaling pathways, supporting the role of the pathway in the pathogenesis of inflammatory diseases. Inhibition of mTOR signaling using specific pharmacological inhibitors could offer therapeutic promise in several inflammatory-associated diseases. In this review, we summarize recent findings on the regulatory effects of mTOR signaling on inflammation and the therapeutic potency of mTOR pharmacological inhibitors in the treatment of inflammatory diseases including cancer, neurodegenerative diseases, atherosclerosis, sepsis, and rheumatoid arthritis for a better understanding and hence a better management of these diseases. Mammalian target of rapamycin (mTOR) signaling pathway controls cell energy metabolism. There is an interplay between mTOR and proinflammatory signaling pathways, supporting the role of the pathway in the pathogenesis of inflammatory diseases. Inhibition of mTOR signaling using specific pharmacological inhibitors could offer therapeutic promise in several inflammatory‐associated diseases. In this review, we summarize recent findings on the regulatory effects of mTOR signaling on inflammation and the therapeutic potency of mTOR pharmacological inhibitors in the treatment of inflammatory diseases including cancer, neurodegenerative diseases, atherosclerosis, sepsis, and rheumatoid arthritis for a better understanding and hence a better management of these diseases. In this review, we summarize recent findings on the regulatory effects of mTOR signaling on inflammation and the therapeutic potency of mTOR pharmacological inhibitors in the treatment of inflammatory diseases including cancer, neurodegenerative diseases, atherosclerosis, sepsis, and rheumatoid arthritis for a better understanding and hence a better management of these diseases. |
| Author | Soltani, Arash Khazaei, Majid Boroumand, Nadia Ryzhikov, Mikhail Soleimanpour, Saman Bahreyni, Amirhossein Avan, Amir Roshan, Mostafa karimi Hassanian, Seyed Mahdi |
| Author_xml | – sequence: 1 givenname: Arash surname: Soltani fullname: Soltani, Arash organization: Mashhad University of Medical Sciences – sequence: 2 givenname: Amirhossein surname: Bahreyni fullname: Bahreyni, Amirhossein organization: Mazandaran University of Medical Sciences – sequence: 3 givenname: Nadia surname: Boroumand fullname: Boroumand, Nadia organization: Mashhad University of Medical Sciences – sequence: 4 givenname: Mostafa karimi surname: Roshan fullname: Roshan, Mostafa karimi organization: Mashhad University of Medical Sciences – sequence: 5 givenname: Majid orcidid: 0000-0002-7979-5699 surname: Khazaei fullname: Khazaei, Majid organization: Mashhad University of Medical Sciences – sequence: 6 givenname: Mikhail surname: Ryzhikov fullname: Ryzhikov, Mikhail organization: St. Louis University, School of Medicine – sequence: 7 givenname: Saman surname: Soleimanpour fullname: Soleimanpour, Saman organization: Mashhad University of Medical Sciences – sequence: 8 givenname: Amir orcidid: 0000-0002-4968-0962 surname: Avan fullname: Avan, Amir email: avana@mums.ac.ir organization: Mashhad University of Medical Sciences – sequence: 9 givenname: Seyed Mahdi orcidid: 0000-0002-5247-4043 surname: Hassanian fullname: Hassanian, Seyed Mahdi email: hasanianmehrm@mums.ac.ir organization: Mashhad University of Medical Sciences |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29165795$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kc1uGyEUhVGVqnHSLvoCFVI3rdRJgGGYYRlZ_VWkVJW7Rpi5Y2MxMAWmlZ8irxxcO5uoXXHR_c4BnXOBznzwgNBrSq4oIex6Z6YrJlgrnqEFJbKtuGjYGVqUHa1kw-k5ukhpRwiRsq5foHMmqWha2SzQ_WoLUU8wZ2vwFDJ4s8dhwOPq7gdOduO1s36Dp62OozbBhY012mHrt3Ztc4ipjDhvAecIOo_g80E9xWD94PQ46sLscW8T6ATpAzZzjAcoZZ3ncte-xxPENIHJ9jekl-j5oF2CV6fzEv389HG1_FLd3n3-ury5rQynUlRAZE8E7wjn3VoOXd1DRynjYmiEaETdG2n0YBom27XspWhMKzQ0ZiCSkqHV9SV6d_QtX_01Q8pqtMmAc9pDmJMqj7Rc1Fyygr59gu7CHEswSTFCOta1LakL9eZEzesRejVFO-q4V49RF-D6CJgYUoowKGNLCDb4HLV1ihJ1KFOVMtXfMovi_RPFo-m_2JP7H-tg_39QfVt-PyoeAC_hsDE |
| CitedBy_id | crossref_primary_10_1007_s12325_022_02419_4 crossref_primary_10_1016_j_bbrc_2022_03_004 crossref_primary_10_3389_fgene_2024_1383452 crossref_primary_10_3389_fphar_2018_01520 crossref_primary_10_1186_s40560_019_0365_5 crossref_primary_10_3390_nu14142824 crossref_primary_10_1002_jcp_27192 crossref_primary_10_1002_jcp_29491 crossref_primary_10_1016_j_lfs_2020_117470 crossref_primary_10_1002_jcb_28401 crossref_primary_10_1007_s13402_019_00456_w crossref_primary_10_3389_fnagi_2019_00314 crossref_primary_10_1039_C9RA04726C crossref_primary_10_1016_j_aqrep_2024_102043 crossref_primary_10_3390_pharmaceutics14112277 crossref_primary_10_1002_biof_1777 crossref_primary_10_3390_ijms23031696 crossref_primary_10_1016_j_biochi_2019_08_003 crossref_primary_10_1038_s42003_022_03804_z crossref_primary_10_1007_s10616_020_00441_4 crossref_primary_10_1016_j_prostaglandins_2024_106918 crossref_primary_10_1093_burnst_tkae006 crossref_primary_10_3390_ijms231911365 crossref_primary_10_1139_cjpp_2020_0487 crossref_primary_10_3389_fphar_2020_00425 crossref_primary_10_1007_s11033_021_06458_y crossref_primary_10_1007_s11033_023_08283_x crossref_primary_10_1042_BST20170121 crossref_primary_10_3389_fphar_2023_1083875 crossref_primary_10_1016_j_npep_2025_102533 |
| Cites_doi | 10.1038/nature01322 10.1155/2017/8135934 10.1101/gad.12.4.502 10.1146/annurev-immunol-020711-075024 10.3389/fimmu.2017.00720 10.1152/japplphysiol.01026.2004 10.1152/ajpendo.00204.2007 10.1038/nri3901 10.1038/nature10912 10.1038/ni.1645 10.1038/nature06730 10.1172/JCI83136 10.4172/2155-9899.1000160 10.1111/j.1462-5822.2006.00699.x 10.1182/blood-2010-09-310888 10.1111/jth.12899 10.1016/j.neuint.2014.06.015 10.1002/eji.200838761 10.1111/j.1600-6143.2010.03302.x 10.1097/SHK.0b013e3181ecb57c 10.1101/cshperspect.a011593 10.1093/hmg/ddn192 10.4103/2319-4170.110365 10.1101/gad.1662308 10.1016/j.ceb.2011.09.003 10.1242/jcs.125773 10.3892/ijmm.2013.1494 10.1186/s13075-017-1366-1 10.1038/nri2402 10.1016/j.mehy.2012.08.022 10.1152/ajpendo.00366.2001 10.1016/j.cell.2007.05.058 10.1016/j.metabol.2006.08.025 10.1002/eji.201646491 10.4049/jimmunol.1303492 10.1016/j.immuni.2008.08.012 10.1002/art.27504 10.1111/imm.12126 10.1007/s00726-014-1836-6 10.1038/cddiscovery.2015.16 10.1161/CIRCULATIONAHA.117.027612 10.1242/jcs.051011 10.1038/ni.2936 10.1111/bcp.12804 10.1074/jbc.M111.258053 10.1097/01.mco.0000165003.16578.2d 10.1111/jth.13580 10.1007/s11926-016-0622-8 10.1016/j.nbd.2015.10.001 10.1152/ajprenal.00014.2012 10.1152/ajprenal.00015.2012 10.1016/j.cell.2006.02.016 10.1182/blood-2008-02-137430 10.1038/srep31142 10.1158/0008-5472.CAN-07-1232 10.1146/annurev-nutr-071714-034355 10.1111/bcp.12820 10.1038/nri2546 10.1016/j.molcel.2006.03.029 10.4049/jimmunol.1200069 10.1016/j.tibs.2006.04.003 10.1152/physiol.00044.2010 10.1016/j.cell.2017.02.004 10.1111/j.1600-6143.2009.02832.x 10.1097/SHK.0000000000000304 10.1038/ncb1183 10.1038/nature01320 10.1159/000369680 10.1371/journal.pone.0146517 10.1016/j.cell.2010.02.029 10.1007/s10495-017-1387-x |
| ContentType | Journal Article |
| Copyright | 2017 Wiley Periodicals, Inc. 2018 Wiley Periodicals, Inc. |
| Copyright_xml | – notice: 2017 Wiley Periodicals, Inc. – notice: 2018 Wiley Periodicals, Inc. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7TK 7U7 8FD C1K FR3 K9. P64 RC3 7X8 |
| DOI | 10.1002/jcp.26276 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Neurosciences Abstracts Toxicology Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Genetics Abstracts Technology Research Database Toxicology Abstracts ProQuest Health & Medical Complete (Alumni) Engineering Research Database Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Genetics Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology Biology |
| EISSN | 1097-4652 |
| EndPage | 4790 |
| ExternalDocumentID | 29165795 10_1002_jcp_26276 JCP26276 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article Review |
| GrantInformation_xml | – fundername: Iran National Science Foundation funderid: 96006612 – fundername: Mashhad University of Medical Sciences funderid: 951824 |
| GroupedDBID | --- -DZ -~X .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 31~ 33P 36B 3O- 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52S 52T 52U 52W 52X 53G 5GY 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 85S 8UM 930 9M8 A03 AAESR AAEVG AAHHS AAHQN AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDPE ABEFU ABEML ABIJN ABJNI ABPPZ ABPVW ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACNCT ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHMBA AIAGR AITYG AIURR AIWBW AJBDE AJXKR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AUFTA AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMNLL BMXJE BNHUX BQCPF BROTX BRXPI BY8 CS3 D-E D-F DCZOG DPXWK DR1 DR2 DRFUL DRSTM DU5 EBD EBS EJD EMB EMOBN F00 F01 F04 F5P FEDTE G-S G.N GNP GODZA H.T H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ H~9 IH2 IX1 J0M JPC KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M56 MEWTI MK4 MRFUL MRSTM MSFUL MSSTM MVM MXFUL MXSTM N04 N05 N9A NEJ NF~ NNB O66 O9- OHT OIG P2P P2W P2X P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO ROL RWI RWR RX1 RYL S10 SAMSI SUPJJ SV3 TN5 TWZ UB1 UPT V2E V8K VQP W8V W99 WBKPD WH7 WIB WIH WIK WJL WNSPC WOHZO WQJ WRC WXSBR WYB WYISQ X7M XG1 XJT XOL XPP XSW XV2 Y6R YQT YZZ ZGI ZXP ZZTAW ~IA ~WT AAMMB AAYXX ABUFD ADXHL AEFGJ AETEA AEYWJ AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY CITATION O8X CGR CUY CVF ECM EIF NPM PKN 7TK 7U7 8FD C1K FR3 K9. P64 RC3 7X8 |
| ID | FETCH-LOGICAL-c4196-e09d06480448b9f83de811246f566563dc9cafc5297b9d965c76ae5cf0910f7a3 |
| IEDL.DBID | DRFUL |
| ISICitedReferencesCount | 41 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000426190900034&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0021-9541 1097-4652 |
| IngestDate | Thu Jul 10 23:55:12 EDT 2025 Sat Nov 29 14:44:59 EST 2025 Wed Feb 19 02:32:28 EST 2025 Sat Nov 29 02:48:54 EST 2025 Tue Nov 18 22:23:45 EST 2025 Wed Jan 22 16:47:05 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | inflamatory diseases pharmacological inhibitors mammalian target of rapamycin inflammation |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor 2017 Wiley Periodicals, Inc. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4196-e09d06480448b9f83de811246f566563dc9cafc5297b9d965c76ae5cf0910f7a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-7979-5699 0000-0002-4968-0962 0000-0002-5247-4043 |
| PMID | 29165795 |
| PQID | 2008287703 |
| PQPubID | 1006363 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_1967463492 proquest_journals_2008287703 pubmed_primary_29165795 crossref_citationtrail_10_1002_jcp_26276 crossref_primary_10_1002_jcp_26276 wiley_primary_10_1002_jcp_26276_JCP26276 |
| PublicationCentury | 2000 |
| PublicationDate | June 2018 |
| PublicationDateYYYYMMDD | 2018-06-01 |
| PublicationDate_xml | – month: 06 year: 2018 text: June 2018 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hoboken |
| PublicationTitle | Journal of cellular physiology |
| PublicationTitleAlternate | J Cell Physiol |
| PublicationYear | 2018 |
| Publisher | Wiley Subscription Services, Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc |
| References | 2015; 35 2010; 10 2017; 8 2012; 485 2013; 4 2006; 31 2011; 117 2013; 126 2008; 38 2008; 9 2004; 6 2008; 8 2010; 140 2010; 62 2007; 293 2006; 22 2008; 29 2007; 130 2002; 420 2015; 43 2009; 122 2014; 15 2016; 85 2008; 22 2011; 23 2016; 82 2011; 26 2008; 112 2017; 168 2007; 67 1998; 12 2016; 46 2011; 286 2006; 124 2015; 13 2015; 1 2015; 15 2012; 188 2017; 2017 2012b; 303 2017; 22 2008; 17 2006; 8 2014; 46 2011; 35 2013; 140 2016; 126 2014; 192 2016; 18 2012; 79 2017; 136 2007; 56 2012; 30 2016; 11 2016; 6 2002; 282 2013; 36 2017; 15 2013; 32 2005; 8 2009; 9 2005; 98 2017 2017; 19 2008; 452 2012; 4 2012a; 303 2014; 76 Wang D. (e_1_2_4_65_1) 2017; 2017 e_1_2_4_40_1 e_1_2_4_63_1 e_1_2_4_61_1 e_1_2_4_21_1 e_1_2_4_44_1 e_1_2_4_67_1 e_1_2_4_23_1 e_1_2_4_42_1 e_1_2_4_25_1 e_1_2_4_48_1 e_1_2_4_27_1 e_1_2_4_46_1 e_1_2_4_69_1 Wang B. (e_1_2_4_64_1) 2015; 35 e_1_2_4_3_1 e_1_2_4_5_1 e_1_2_4_7_1 Oaks Z. (e_1_2_4_47_1) 2016; 18 e_1_2_4_9_1 e_1_2_4_52_1 e_1_2_4_73_1 e_1_2_4_50_1 e_1_2_4_10_1 e_1_2_4_31_1 e_1_2_4_56_1 e_1_2_4_12_1 e_1_2_4_33_1 e_1_2_4_54_1 e_1_2_4_14_1 e_1_2_4_35_1 e_1_2_4_16_1 e_1_2_4_37_1 e_1_2_4_58_1 e_1_2_4_18_1 e_1_2_4_39_1 Wong M. (e_1_2_4_71_1) 2013; 36 e_1_2_4_41_1 e_1_2_4_60_1 e_1_2_4_20_1 e_1_2_4_45_1 e_1_2_4_66_1 e_1_2_4_22_1 e_1_2_4_43_1 e_1_2_4_24_1 e_1_2_4_49_1 e_1_2_4_26_1 e_1_2_4_68_1 e_1_2_4_28_1 e_1_2_4_2_1 e_1_2_4_4_1 e_1_2_4_70_1 e_1_2_4_6_1 e_1_2_4_8_1 e_1_2_4_51_1 e_1_2_4_30_1 e_1_2_4_72_1 e_1_2_4_32_1 e_1_2_4_55_1 e_1_2_4_53_1 e_1_2_4_13_1 e_1_2_4_36_1 e_1_2_4_59_1 Tang M. W. (e_1_2_4_62_1) 2017; 8 Dan H. C. (e_1_2_4_11_1) 2007; 67 e_1_2_4_15_1 Laplante M. (e_1_2_4_34_1) 2012; 4 e_1_2_4_38_1 e_1_2_4_57_1 Kurdi A. (e_1_2_4_29_1) 2017 e_1_2_4_17_1 e_1_2_4_19_1 |
| References_xml | – volume: 12 start-page: 502 issue: 4 year: 1998 end-page: 513 article-title: 4E‐BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway publication-title: Genes & Development – volume: 2017 start-page: 8135934 year: 2017 article-title: Roles of cells from the arterial vessel wall in atherosclerosis publication-title: Mediators of Inflammation – volume: 9 start-page: 1157 issue: 10 year: 2008 end-page: 1164 article-title: Toll‐like receptor‐mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin‐sensitive PI(3)K‐mTOR‐p70S6K pathway publication-title: Nature Immunology – volume: 117 start-page: 4273 issue: 16 year: 2011 end-page: 4283 article-title: Inhibition of mTOR blocks the anti‐inflammatory effects of glucocorticoids in myeloid immune cells publication-title: Blood – volume: 140 start-page: 179 issue: 2 year: 2013 end-page: 190 article-title: Rapamycin unbalances the polarization of human macrophages to M1 publication-title: Immunology – volume: 112 start-page: 635 issue: 3 year: 2008 end-page: 643 article-title: Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide‐induced interleukin‐12 production in dendritic cells publication-title: Blood – volume: 30 start-page: 39 year: 2012 end-page: 68 article-title: Regulation of immune responses by mTOR publication-title: Annual Review of Immunology – volume: 122 start-page: 3589 issue: Pt 20 year: 2009 end-page: 3594 article-title: MTOR signaling at a glance publication-title: Journal of Cell Science – volume: 43 start-page: 344 issue: 4 year: 2015 end-page: 351 article-title: Sepsis attenuates the anabolic response to skeletal muscle contraction publication-title: Shock – volume: 22 start-page: 1490 issue: 11 year: 2008 end-page: 1500 article-title: Akt‐dependent regulation of NF‐κB is controlled by mTOR and Raptor in association with IKK publication-title: Genes & Development – volume: 282 start-page: E336 issue: 2 year: 2002 end-page: E347 article-title: TNF‐alpha impairs heart and skeletal muscle protein synthesis by altering translation initiation publication-title: American Journal of Physiology Endocrinology and Metabolism – volume: 15 start-page: 749 issue: 8 year: 2014 end-page: 757 article-title: The metabolic checkpoint kinase mTOR is essential for IL‐15 signaling during the development and activation of NK cells publication-title: Nature Immunology – volume: 11 start-page: e0146517 issue: 1 year: 2016 article-title: The neuroprotective effect of rapamycin as a modulator of the mTOR‐NF‐kappaB axis during retinal inflammation publication-title: PLoS ONE – volume: 9 start-page: 2655 issue: 12 year: 2009 end-page: 2661 article-title: The multifunctional role of mTOR in innate immunity: Implications for transplant immunity publication-title: American Journal of Transplantation – volume: 4 start-page: a011593 issue: 2 year: 2012 article-title: MTOR signaling publication-title: Cold Spring Harbor Perspectives in Biology – volume: 420 start-page: 846 issue: 6917 year: 2002 end-page: 852 article-title: Points of control in inflammation publication-title: Nature – volume: 140 start-page: 871 issue: 6 year: 2010 end-page: 882 article-title: Nonresolving inflammation publication-title: Cell – volume: 485 start-page: 55 issue: 7396 year: 2012 end-page: 61 article-title: The translational landscape of mTOR signalling steers cancer initiation and metastasis publication-title: Nature – volume: 46 start-page: 2787 issue: 12 year: 2014 end-page: 2798 article-title: Sepsis‐induced changes in amino acid transporters and leucine signaling via mTOR in skeletal muscle publication-title: Amino Acids – volume: 188 start-page: 4736 issue: 10 year: 2012 end-page: 4740 article-title: Cutting edge: MTORC1 in intestinal CD11c+ CD11b+ dendritic cells regulates intestinal homeostasis by promoting IL‐10 production publication-title: Journal of Immunology – volume: 35 start-page: 117 issue: 2 year: 2011 end-page: 125 article-title: Sepsis‐induced alterations in protein‐protein interactions within mTOR complex 1 and the modulating effect of leucine on muscle protein synthesis publication-title: Shock (Augusta, Ga) – volume: 6 start-page: 1122 issue: 11 year: 2004 end-page: 1128 article-title: Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive publication-title: Nature Cell Biology – volume: 8 start-page: 255 issue: 3 year: 2005 end-page: 263 article-title: Skeletal muscle cytokines: Regulation by pathogen‐associated molecules and catabolic hormones publication-title: Current Opinion in Clinical Nutrition and Metabolic Care – volume: 35 start-page: 116 issue: 1 year: 2015 end-page: 125 article-title: Rapamycin attenuates aldosterone‐induced tubulointerstitial inflammation and fibrosis publication-title: Cellular Physiology and Biochemistry – volume: 126 start-page: 3236 issue: 9 year: 2016 end-page: 3246 article-title: Loss of ABCG1 influences regulatory T cell differentiation and atherosclerosis publication-title: The Journal of Clinical Investigation – volume: 6 start-page: 31142 year: 2016 article-title: The role of mTOR signalling in the regulation of skeletal muscle mass in a rodent model of resistance exercise publication-title: Scientific Reports – volume: 79 start-page: 757 issue: 6 year: 2012 end-page: 760 article-title: Combined therapeutic application of mTOR inhibitor and vitamin D(3) for inflammatory bone destruction of rheumatoid arthritis publication-title: Medical Hypotheses – volume: 22 start-page: 1138 issue: 9 year: 2017 end-page: 1146 article-title: Astragalus polysaccharides inhibits cell growth and pro‐inflammatory response in IL‐1β‐stimulated fibroblast‐like synoviocytes by enhancement of autophagy via PI3 K/AKT/mTOR inhibition publication-title: Apoptosis – volume: 76 start-page: 23 year: 2014 end-page: 31 article-title: Melatonin reduced microglial activation and alleviated neuroinflammation induced neuron degeneration in experimental traumatic brain injury: Possible involvement of mTOR pathway publication-title: Neurochemistry International – volume: 32 start-page: 1215 issue: 5 year: 2013 end-page: 1221 article-title: Knockdown of mTOR by lentivirusmediated RNA interference suppresses atherosclerosis and stabilizes plaques via a decrease of macrophages by autophagy in apolipoprotein Edeficient mice publication-title: International Journal of Molecular Medicine – volume: 15 start-page: 599 issue: 10 year: 2015 end-page: 614 article-title: Regulation of innate immune cell function by mTOR publication-title: Nature Reviews Immunology – volume: 126 start-page: 1713 issue: 8 year: 2013 end-page: 1719 article-title: Regulation of mTORC1 and its impact on gene expression at a glance publication-title: Journal of Cell Science – volume: 31 start-page: 342 issue: 6 year: 2006 end-page: 348 article-title: Ribosomal protein S6 phosphorylation: From protein synthesis to cell size publication-title: Trends in Biochemical Sciences – volume: 98 start-page: 911 issue: 3 year: 2005 end-page: 917 article-title: IL‐6‐induced skeletal muscle atrophy publication-title: Journal of Applied Physiology – volume: 4 start-page: 160 year: 2013 article-title: Intracellular signaling pathways in rheumatoid arthritis publication-title: Journal of Clinical & Cellular Immunology – volume: 46 start-page: 2409 issue: 10 year: 2016 end-page: 2419 article-title: Protein phosphatase 1 abrogates IRF7‐mediated type I IFN response in antiviral immunity publication-title: European Journal of Immunology – volume: 9 start-page: 324 issue: 5 year: 2009 end-page: 337 article-title: Immunoregulatory functions of mTOR inhibition publication-title: Nature Reviews Immunology – volume: 19 start-page: 159 issue: 1 year: 2017 article-title: Factors associated with initial or subsequent choice of biologic disease‐modifying antirheumatic drugs for treatment of rheumatoid arthritis publication-title: Arthritis Research & Therapy – volume: 56 start-page: 49 issue: 1 year: 2007 end-page: 57 article-title: Sepsis‐induced suppression of skeletal muscle translation initiation mediated by tumor necrosis factor alpha publication-title: Metabolism: Clinical and Experimental – volume: 10 start-page: 2604 issue: 12 year: 2010 end-page: 2614 article-title: Comparative transcriptional and phenotypic peripheral blood analysis of kidney recipients under cyclosporin A or sirolimus monotherapy publication-title: American Journal of Transplantation – volume: 82 start-page: 1267 issue: 5 year: 2016 end-page: 1279 article-title: Potential therapeutic effects of mTOR inhibition in atherosclerosis publication-title: British Journal of Clinical Pharmacology – volume: 29 start-page: 565 issue: 4 year: 2008 end-page: 577 article-title: The TSC‐mTOR signaling pathway regulates the innate inflammatory response publication-title: Immunity – volume: 286 start-page: 44295 issue: 52 year: 2011 end-page: 44305 article-title: Mammalian target of rapamycin complex 2 (mTORC2) negatively regulates Toll‐like receptor 4‐mediated inflammatory response via FoxO1 publication-title: The Journal of Biological Chemistry – volume: 420 start-page: 860 issue: 6917 year: 2002 end-page: 867 article-title: Inflammation and cancer publication-title: Nature – volume: 18 start-page: 73 issue: 12 year: 2016 article-title: Activation of the mechanistic target of rapamycin in SLE: explosion of evidence in the last five years publication-title: Current Rheumatology Reports – volume: 35 start-page: 321 year: 2015 end-page: 348 article-title: The roles of mTOR complexes in lipid metabolism publication-title: Annual Review of Nutrition – volume: 124 start-page: 823 issue: 4 year: 2006 end-page: 835 article-title: Innate immunity gone awry: Linking microbial infections to chronic inflammation and cancer publication-title: Cell – volume: 8 start-page: 776 issue: 10 year: 2008 end-page: 787 article-title: Harmful molecular mechanisms in sepsis publication-title: Nature Reviews Immunology – volume: 15 start-page: 213 issue: 2 year: 2017 end-page: 218 article-title: Inorganic polyphosphate: A key modulator of inflammation publication-title: Journal of Thrombosis and Haemostasis – volume: 13 start-page: 860 issue: 5 year: 2015 end-page: 871 article-title: Inorganic polyphosphate elicits pro‐inflammatory responses through activation of the mammalian target of rapamycin complexes 1 and 2 in vascular endothelial cells publication-title: Journal of Thrombosis and Haemostasis – volume: 26 start-page: 83 issue: 2 year: 2011 end-page: 96 article-title: MTor signaling in skeletal muscle during sepsis and inflammation: Where does it all go wrong publication-title: Physiology – volume: 303 start-page: F1 issue: 1 year: 2012a end-page: 10 article-title: Mammalian target of rapamycin and the kidney. I. The signaling pathway publication-title: American Journal of Physiology. Renal Physiology – year: 2017 article-title: MTOR inhibition & cardiovascular diseases: Dyslipidemia and atherosclerosis publication-title: Transplantation – volume: 130 start-page: 440 issue: 3 year: 2007 end-page: 455 article-title: IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway publication-title: Cell – volume: 192 start-page: 6009 issue: 12 year: 2014 end-page: 6019 article-title: MTOR signaling inhibition modulates macrophage/microglia‐mediated neuroinflammation and secondary injury via regulatory T cells after focal ischemia publication-title: Journal of Immunology (Baltimore, Md: 1950) – volume: 136 start-page: 464 issue: 5 year: 2017 end-page: 475 article-title: Human plasma thioredoxin‐80 increases with age and in apoE mice induces inflammation, angiogenesis and atherosclerosis publication-title: Circulation – volume: 8 start-page: 720 year: 2017 article-title: Insight into the endocrine system and the immune system: A review of the inflammatory role of prolactin in rheumatoid arthritis and psoriatic arthritis publication-title: Frontiers in Immunology – volume: 67 start-page: 6263 issue: 13 year: 2007 end-page: 6269 article-title: Regulation of mammalian target of rapamycin activity in PTEN‐inactive prostate cancer cells by I kappa B kinase alpha publication-title: Cancer Research – volume: 82 start-page: 1245 issue: 5 year: 2016 end-page: 1266 article-title: Targeting molecules to medicine with mTOR, autophagy and neurodegenerative disorders publication-title: British Journal of Clinical Pharmacology – volume: 85 start-page: 144 year: 2016 end-page: 154 article-title: MTOR pathway inhibition prevents neuroinflammation and neuronal death in a mouse model of cerebral palsy publication-title: Neurobiology of Disease – volume: 452 start-page: 323 issue: 7185 year: 2008 end-page: 328 article-title: Translational control of the innate immune response through IRF‐7 publication-title: Nature – volume: 293 start-page: E453 issue: 2 year: 2007 end-page: E459 article-title: Regulation of muscle protein synthesis during sepsis and inflammation publication-title: American Journal of Physiology Endocrinology and Metabolism – volume: 62 start-page: 2294 issue: 8 year: 2010 end-page: 2302 article-title: Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis publication-title: Arthritis and Rheumatism – volume: 8 start-page: 1158 issue: 7 year: 2006 end-page: 1171 article-title: Intracellular network of phosphatidylinositol 3‐kinase, mammalian target of the rapamycin/70kDa ribosomal S6 kinase 1, and mitogen‐activated protein kinases pathways for regulating mycobacteria‐induced IL‐23 expression in human macrophages publication-title: Cellular Microbiology – volume: 23 start-page: 744 issue: 6 year: 2011 end-page: 755 article-title: MTOR signaling in disease publication-title: Current Opinion in Cell Biology – volume: 1 start-page: 15016 year: 2015 article-title: MTORC2 controls cancer cell survival by modulating gluconeogenesis publication-title: Cell Death Discovery – volume: 17 start-page: 2934 issue: 19 year: 2008 end-page: 2948 article-title: Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1 publication-title: Human Molecular Genetics – volume: 168 start-page: 960 issue: 6 year: 2017 end-page: 976 article-title: MTOR signaling in growth, metabolism, and disease publication-title: Cell – volume: 36 start-page: 40 issue: 2 year: 2013 end-page: 50 article-title: Mammalian target of rapamycin (mTOR) pathways in neurological diseases publication-title: Biomedical Journal – volume: 303 start-page: F180 issue: 2 year: 2012b end-page: F191 article-title: Mammalian target of rapamycin and the kidney. II. Pathophysiology and therapeutic implications publication-title: American Journal of Physiology. Renal Physiology – volume: 22 start-page: 159 issue: 2 year: 2006 end-page: 168 article-title: Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB publication-title: Molecular Cell – volume: 38 start-page: 2981 issue: 11 year: 2008 end-page: 2992 article-title: Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells publication-title: European Journal of Immunology – ident: e_1_2_4_10_1 doi: 10.1038/nature01322 – volume: 2017 start-page: 8135934 year: 2017 ident: e_1_2_4_65_1 article-title: Roles of cells from the arterial vessel wall in atherosclerosis publication-title: Mediators of Inflammation doi: 10.1155/2017/8135934 – ident: e_1_2_4_17_1 doi: 10.1101/gad.12.4.502 – ident: e_1_2_4_52_1 doi: 10.1146/annurev-immunol-020711-075024 – volume: 8 start-page: 720 year: 2017 ident: e_1_2_4_62_1 article-title: Insight into the endocrine system and the immune system: A review of the inflammatory role of prolactin in rheumatoid arthritis and psoriatic arthritis publication-title: Frontiers in Immunology doi: 10.3389/fimmu.2017.00720 – ident: e_1_2_4_18_1 doi: 10.1152/japplphysiol.01026.2004 – ident: e_1_2_4_32_1 doi: 10.1152/ajpendo.00204.2007 – ident: e_1_2_4_70_1 doi: 10.1038/nri3901 – ident: e_1_2_4_21_1 doi: 10.1038/nature10912 – ident: e_1_2_4_4_1 doi: 10.1038/ni.1645 – ident: e_1_2_4_8_1 doi: 10.1038/nature06730 – ident: e_1_2_4_7_1 doi: 10.1172/JCI83136 – ident: e_1_2_4_41_1 doi: 10.4172/2155-9899.1000160 – ident: e_1_2_4_73_1 doi: 10.1111/j.1462-5822.2006.00699.x – ident: e_1_2_4_69_1 doi: 10.1182/blood-2010-09-310888 – ident: e_1_2_4_19_1 doi: 10.1111/jth.12899 – ident: e_1_2_4_14_1 doi: 10.1016/j.neuint.2014.06.015 – ident: e_1_2_4_59_1 doi: 10.1002/eji.200838761 – ident: e_1_2_4_2_1 doi: 10.1111/j.1600-6143.2010.03302.x – ident: e_1_2_4_25_1 doi: 10.1097/SHK.0b013e3181ecb57c – volume: 4 start-page: a011593 issue: 2 year: 2012 ident: e_1_2_4_34_1 article-title: MTOR signaling publication-title: Cold Spring Harbor Perspectives in Biology doi: 10.1101/cshperspect.a011593 – ident: e_1_2_4_54_1 doi: 10.1093/hmg/ddn192 – volume: 36 start-page: 40 issue: 2 year: 2013 ident: e_1_2_4_71_1 article-title: Mammalian target of rapamycin (mTOR) pathways in neurological diseases publication-title: Biomedical Journal doi: 10.4103/2319-4170.110365 – ident: e_1_2_4_12_1 doi: 10.1101/gad.1662308 – ident: e_1_2_4_13_1 doi: 10.1016/j.ceb.2011.09.003 – ident: e_1_2_4_35_1 doi: 10.1242/jcs.125773 – ident: e_1_2_4_67_1 doi: 10.3892/ijmm.2013.1494 – ident: e_1_2_4_23_1 doi: 10.1186/s13075-017-1366-1 – ident: e_1_2_4_53_1 doi: 10.1038/nri2402 – ident: e_1_2_4_27_1 doi: 10.1016/j.mehy.2012.08.022 – ident: e_1_2_4_31_1 doi: 10.1152/ajpendo.00366.2001 – ident: e_1_2_4_37_1 doi: 10.1016/j.cell.2007.05.058 – ident: e_1_2_4_30_1 doi: 10.1016/j.metabol.2006.08.025 – ident: e_1_2_4_66_1 doi: 10.1002/eji.201646491 – ident: e_1_2_4_72_1 doi: 10.4049/jimmunol.1303492 – ident: e_1_2_4_68_1 doi: 10.1016/j.immuni.2008.08.012 – ident: e_1_2_4_6_1 doi: 10.1002/art.27504 – ident: e_1_2_4_44_1 doi: 10.1111/imm.12126 – ident: e_1_2_4_36_1 doi: 10.1007/s00726-014-1836-6 – ident: e_1_2_4_26_1 doi: 10.1038/cddiscovery.2015.16 – ident: e_1_2_4_9_1 doi: 10.1161/CIRCULATIONAHA.117.027612 – ident: e_1_2_4_33_1 doi: 10.1242/jcs.051011 – ident: e_1_2_4_42_1 doi: 10.1038/ni.2936 – ident: e_1_2_4_40_1 doi: 10.1111/bcp.12804 – ident: e_1_2_4_3_1 doi: 10.1074/jbc.M111.258053 – ident: e_1_2_4_15_1 doi: 10.1097/01.mco.0000165003.16578.2d – ident: e_1_2_4_20_1 doi: 10.1111/jth.13580 – volume: 18 start-page: 73 issue: 12 year: 2016 ident: e_1_2_4_47_1 article-title: Activation of the mechanistic target of rapamycin in SLE: explosion of evidence in the last five years publication-title: Current Rheumatology Reports doi: 10.1007/s11926-016-0622-8 – ident: e_1_2_4_60_1 doi: 10.1016/j.nbd.2015.10.001 – ident: e_1_2_4_38_1 doi: 10.1152/ajprenal.00014.2012 – ident: e_1_2_4_39_1 doi: 10.1152/ajprenal.00015.2012 – ident: e_1_2_4_24_1 doi: 10.1016/j.cell.2006.02.016 – ident: e_1_2_4_50_1 doi: 10.1182/blood-2008-02-137430 – ident: e_1_2_4_48_1 doi: 10.1038/srep31142 – volume: 67 start-page: 6263 issue: 13 year: 2007 ident: e_1_2_4_11_1 article-title: Regulation of mammalian target of rapamycin activity in PTEN‐inactive prostate cancer cells by I kappa B kinase alpha publication-title: Cancer Research doi: 10.1158/0008-5472.CAN-07-1232 – ident: e_1_2_4_5_1 doi: 10.1146/annurev-nutr-071714-034355 – ident: e_1_2_4_28_1 doi: 10.1111/bcp.12820 – ident: e_1_2_4_63_1 doi: 10.1038/nri2546 – ident: e_1_2_4_57_1 doi: 10.1016/j.molcel.2006.03.029 – ident: e_1_2_4_49_1 doi: 10.4049/jimmunol.1200069 – ident: e_1_2_4_55_1 doi: 10.1016/j.tibs.2006.04.003 – ident: e_1_2_4_16_1 doi: 10.1152/physiol.00044.2010 – ident: e_1_2_4_58_1 doi: 10.1016/j.cell.2017.02.004 – year: 2017 ident: e_1_2_4_29_1 article-title: MTOR inhibition & cardiovascular diseases: Dyslipidemia and atherosclerosis publication-title: Transplantation – ident: e_1_2_4_56_1 doi: 10.1111/j.1600-6143.2009.02832.x – ident: e_1_2_4_61_1 doi: 10.1097/SHK.0000000000000304 – ident: e_1_2_4_22_1 doi: 10.1038/ncb1183 – ident: e_1_2_4_45_1 doi: 10.1038/nature01320 – volume: 35 start-page: 116 issue: 1 year: 2015 ident: e_1_2_4_64_1 article-title: Rapamycin attenuates aldosterone‐induced tubulointerstitial inflammation and fibrosis publication-title: Cellular Physiology and Biochemistry doi: 10.1159/000369680 – ident: e_1_2_4_51_1 doi: 10.1371/journal.pone.0146517 – ident: e_1_2_4_46_1 doi: 10.1016/j.cell.2010.02.029 – ident: e_1_2_4_43_1 doi: 10.1007/s10495-017-1387-x |
| SSID | ssj0009933 |
| Score | 2.4363236 |
| SecondaryResourceType | review_article |
| Snippet | Mammalian target of rapamycin (mTOR) signaling pathway controls cell energy metabolism. There is an interplay between mTOR and proinflammatory signaling... |
| SourceID | proquest pubmed crossref wiley |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 4783 |
| SubjectTerms | Animals Anti-Inflammatory Agents - therapeutic use Arteriosclerosis Arthritis Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - enzymology Arthritis, Rheumatoid - immunology Atherosclerosis Atherosclerosis - drug therapy Atherosclerosis - enzymology Atherosclerosis - immunology Cancer Energy metabolism Humans inflamatory diseases inflammation Inflammation - drug therapy Inflammation - enzymology Inflammation - immunology Inflammation Mediators - antagonists & inhibitors Inflammation Mediators - immunology Inflammation Mediators - metabolism Inflammatory diseases Inhibitor drugs Inhibitors mammalian target of rapamycin Metabolism Molecular Targeted Therapy Neoplasms - drug therapy Neoplasms - enzymology Neoplasms - immunology Neurodegenerative diseases Neurodegenerative Diseases - drug therapy Neurodegenerative Diseases - enzymology Neurodegenerative Diseases - immunology Neurological diseases Pathogenesis pharmacological inhibitors Pharmacology Protein Kinase Inhibitors - therapeutic use Rapamycin Rheumatoid arthritis Sepsis Sepsis - drug therapy Sepsis - enzymology Sepsis - immunology Signal transduction Signal Transduction - drug effects Signaling TOR protein TOR Serine-Threonine Kinases - antagonists & inhibitors TOR Serine-Threonine Kinases - immunology TOR Serine-Threonine Kinases - metabolism |
| Title | Therapeutic potency of mTOR signaling pharmacological inhibitors in the treatment of proinflammatory diseases, current status, and perspectives |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjcp.26276 https://www.ncbi.nlm.nih.gov/pubmed/29165795 https://www.proquest.com/docview/2008287703 https://www.proquest.com/docview/1967463492 |
| Volume | 233 |
| WOSCitedRecordID | wos000426190900034&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1097-4652 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0009933 issn: 0021-9541 databaseCode: DRFUL dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1dT9swFL2CwiRetgH76MaQhxDigUBJYjvWnhBbhSYECBXUt8hf0TrRNGraSf0V-8u7dtJEaENC2luiOImdnGsf2_eeC7Cv7CnTXJuAqkQGMY9kIIXSQUZppIwWNPa6BfeX_OoqGQ7FzQp8WcbCVPoQzYKbswzfXzsDl6o8aUVDf-riOGQhZ6uwFiJuaQfWvt727y5bzd06k7z3QqDx6VJYqBeeNDc_Ho7-4piPKasfc_qv_qu2r-FlTTXJWYWNTVix-RZsn-U4zR4vyAHxzp9-VX0LXlQ5KRfb8HvQRmSRYuIo9YJMMjIeXN8S5-0hXQA7KVrJa_ebySj_MVIjl7oHDwmyStK4sLu7sckIZUTf2O_qk3pfqDwiuhKIIi6yaY7nMjekaCNAyzdw1_82OL8I6qwNgY7RnAPbEwZ5TtLDiZ8SWRIZmyCpi1mGzJGyCAGgZaZpKLgSRjCqOZOW6swxl4zL6C108klu3wMRRrkuxiqjkljgc7SMDc9wQsAolZx34XD581JdS5q7zBoPaSXGHKb42VP_2buw1xQtKh2PfxXaWSIgrU259Hk6cVqJCOvC5-YyGqHbWZG5nczLFNvNY-aEHrvwrkJO85YQCTjlgmJlPUCefn36_fzGH3x4ftGPsIEULqmc13agM5vO7SdY179mo3K6C6t8mOzWdvEH0mISdQ |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1dT9RAFL1B0OALKF-uoI7GGB8sLO1Mp5PwQtAN6roSshDemvlqWMJ2G8qa7K_gL3Nn2m1D1MTEtzadaaedc6dnZu49F-C9svux5toETCUyoDySgRRKBxljkTJaMOp1C877fDBILi7EyQIczGNhKn2IZsHNWYYfr52BuwXpvVY19EoXu2Ec8vgRLFGEEeJ76fNp76zfiu7WqeS9GwKj-3NloW6411R--D_6jWQ-5Kz-p9Nb_b_mPoOVmmySwwodz2HB5muwfpjjRHs8Ix-Id__06-pr8KTKSjlbh7thG5NFiokj1TMyych4-POUOH8P6ULYSdGKXruOJqP8cqRGLnkPHhLklaRxYne18Z0RzIi_sd_XJ_XOUPmJ6EoiirjYpimey9yQoo0BLTfgrPdleHQc1HkbAk3RoAPbFQaZTtLFqZ8SWRIZmyCto3GG3JHFEUJAy0yzUHAljIiZ5rG0TGeOu2RcRpuwmE9y-wKIMMoNMlYZlVCB99GSGp7hlCBmTHLegY_z3kt1LWrucmtcp5Ucc5jiZ0_9Z-_Au6ZoUSl5_KnQzhwCaW3Mpc_UiRNLHBs78La5jGbo9lZkbifTMsX35ghCKsIObFXQaZ4SIgVnXDBsrEfI3x-ffjs68Qcv_73oG1g-Hv7op_2vg-_b8BQJXVK5su3A4u3N1L6Cx_rX7ai8eV2bxz24_RV9 |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFD4aHSBeuGwDOgYYhBAPC-sSX2KJl2mj4lKVaurQ3iLfIopoGi0rUn_F_jLHTppoAiQk3hzFTnw5x_5sn_MdgFfaHXIjjI2YTlVERaIiJbWJcsYSbY1kNPAWfB2J8Tg9P5eTDXi39oWp-SHaAzevGWG-9gruSpsfdKyh3035Nuax4Ddgk_ogMj3YPDkdno060t0mlHwwQ2D0cM0sNIgP2sLX16PfQOZ1zBoWneG9_6vufbjbgE1yVEvHA9hwxRZsHxW40Z6vyGsSzD_DufoW3KqjUq624Wra-WSRcuFB9YoscjKffjkl3t5DeRd2Unak136gyaz4NtMzH7wHkwRxJWmN2H1pbDMKM8rfPNzrk-ZmqNonpqaIIt63aYnPqrCk7HxAqx04G76fHn-ImrgNkaGo0JEbSItIJx3g1k_LPE2sSxHWUZ4jdmQ8QREwKjcslkJLKzkzgivHTO6xSy5U8hB6xaJwj4FIq_0k47TVKZX4HaOoFTluCThjSog-vFmPXmYaUnMfW-NHVtMxxxl2exa6vQ8v26xlzeTxp0x7axHIGmWuQqRO3Fji3NiHF-1rVEN_t6IKt1hWGbZbUO6pHvvwqBad9i8xQnAmJMPKBgn5---zT8eTkNj996zP4fbkZJiNPo4_P4E7iOfS2pJtD3qXF0v3FG6an5ez6uJZox2_ACYbFPg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Therapeutic+potency+of+mTOR+signaling+pharmacological+inhibitors+in+the+treatment+of+proinflammatory+diseases%2C+current+status%2C+and+perspectives&rft.jtitle=Journal+of+cellular+physiology&rft.au=Soltani%2C+Arash&rft.au=Bahreyni%2C+Amirhossein&rft.au=Boroumand%2C+Nadia&rft.au=Roshan%2C+Mostafa+karimi&rft.date=2018-06-01&rft.issn=0021-9541&rft.eissn=1097-4652&rft.volume=233&rft.issue=6&rft.spage=4783&rft.epage=4790&rft_id=info:doi/10.1002%2Fjcp.26276&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_jcp_26276 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-9541&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-9541&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-9541&client=summon |